Gamma-butyrobetaine dioxygenase (BBOX1) (BBOX1)

Gamma-butyrobetaine dioxygenase (BBOX1) is a non-heme iron-dependent enzyme that catalyzes the final step of L-carnitine biosynthesis by hydroxylating gamma-butyrobetaine [1.3.1, 1.3.2]. L-carnitine is a critical cofactor for the transport of long-chain fatty acids into the mitochondria for beta-oxidation [1.2.2, 1.3.1]. By inhibiting BBOX1, drugs like Meldonium reduce carnitine availability, forcing a metabolic shift from fatty acid oxidation to glucose oxidation, which is more oxygen-efficient and beneficial in ischemic cardiovascular conditions [1.3.1, 1.3.2]. Beyond its role in metabolism, BBOX1 has emerged as a significant factor in oncology, where it may promote growth in triple-negative breast cancer through non-canonical calcium signaling or act as a tumor suppressor in renal and liver cancers [1.1.3, 1.2.1]. Consequently, BBOX1 is a versatile therapeutic target being explored for its potential in treating metabolic, cardiovascular, and malignant diseases [1.3.2, 1.4.1]. The enzyme is primarily expressed in the kidney and liver, and its activity is dependent on 2-oxoglutarate and molecular oxygen [1.3.1, 1.4.2]. Pharmacological inhibition of BBOX1 is generally well-tolerated, although complete deficiency due to genetic variants can lead to myopathic and neurodevelopmental symptoms [1.1.2, 1.3.5]. Research continues to investigate BBOX1 as a biomarker for disease progression and a target for precision medicine in various cancers [1.1.1, 1.2.1].

Other names

Gamma-butyrobetaine hydroxylaseGBBHBBOXGamma-butyrobetaine,2-oxoglutarate dioxygenase 1

Inhibition of BBOX1 reduces L-carnitine levels, which shifts cellular energy metabolism from fatty acid oxidation to glucose oxidation, thereby reducing oxygen demand in ischemic tissues.